What is it about?

GLP-1 drugs have revolutionized obesity treatment, but they can lead people to lose muscle mass along with fat. And when patients stop treatment, they often regain their weight — primarily as fat. Our study offers a potential solution: an experimental RNA therapy that induces the body to burn calories, thereby enhancing the benefits of GLP-1s. These findings mark the first demonstration that an RNA therapy can turn on thermogenesis, when the body burns calories to produce heat. To achieve this, the experimental treatment essentially reprogrammed white fat, which stores energy, into beige fat, which helps burn it.

Featured Image

Why is it important?

The report is the first to show that an RNA therapy that promotes thermogenesis when combined with the GLP-1 drug semaglutide helps to preserve lean muscle mass. This has therapeutic implications that translate into strategies to overcome muscle loss with drugs that suppress appetite while also opening new avenues to enhance the metabolic improvements achieved with such therapies including the reduction in metabolic dysfunction associated liver disease (MAFLD), insulin resistance, and the maintenance of reduced body weight following weight loss.

Perspectives

This work has been a long and twisting journey, beginning years ago with a question a former member of his lab was trying to answer: How can eating the same number of calories at different times of day lead to different amounts of weight gain? Chelsea Hepler, now at the University of Michigan, led the research addressing that question and identified a link between the body’s internal clock and its ability to turn white fat into beige fat. That work built on research by Rana Gupta, at Duke University, who had identified how the gene ZFP423 acted as a brake in the fat “beiging” process. Rana's studies had originated during his postdoc work with Bruce Spiegelman, a leader in metabolic research. The next question was whether it was possible to release that brake with a drug candidate — something that our team ultimately managed to do with the help of Ionis Pharmaceuticals, a company specializing in RNA-based therapies. This collaboration was also fortuitous in that a former graduate student from our laboratory in Chicago, Mark Perelis, who had relocated many years earlier to San Diego and was immersed in the world of RNA biology, ultimately becoming an investigator at Ionis. Mark was able to test a wide range of the RNA molecules in animals and the functional testing in our lab in Chicago proved to be a lucky chance to merge cutting edge RNA therapeutics with broad approaches in live animal metabolic physiology and molecular studies. The work culminated in the most translational discovery we have made after two decades asking basic questions about how our timing system connects sleep-wake mechanisms to energy balance and metabolism--seemingly distant ideas from uncovering a new therapy for obesity. The work proves again the value of interdisciplinary studies, collaboration, and basic biology. Our goal is to now working on testing similar RNA therapies in human cells. Northwestern University has filed a provisional patent application related to the experimental RNA therapy.

JOSEPH BASS
Northwestern University

Read the Original

This page is a summary of: An RNA thermogenic therapy to preserve lean mass and enhance metabolic health during GLP-1 weight loss, Proceedings of the National Academy of Sciences, September 2026, Proceedings of the National Academy of Sciences,
DOI: 10.1073/pnas.2618845123.
You can read the full text:

Read

Contributors

The following have contributed to this page